Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Economic burden of hepatitis C-associated diseases in the United States.

El Khoury AC, Klimack WK, Wallace C, Razavi H.

J Viral Hepat. 2012 Mar;19(3):153-60. doi: 10.1111/j.1365-2893.2011.01563.x. Epub 2011 Dec 18. Review.

PMID:
22329369
[PubMed - indexed for MEDLINE]
2.

Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas.

El Khoury AC, Wallace C, Klimack WK, Razavi H.

J Med Econ. 2012;15(5):887-96. doi: 10.3111/13696998.2012.681332. Epub 2012 May 24. Review.

PMID:
22458755
[PubMed - indexed for MEDLINE]
3.

All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.

McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI.

J Manag Care Pharm. 2011 Sep;17(7):531-46.

PMID:
21870894
[PubMed - indexed for MEDLINE]
4.

Economic burden associated with patients diagnosed with hepatitis C.

McCombs JS, Yuan Y, Shin J, Saab S.

Clin Ther. 2011 Sep;33(9):1268-80. doi: 10.1016/j.clinthera.2011.07.008. Epub 2011 Aug 12.

PMID:
21840056
[PubMed - indexed for MEDLINE]
5.

The economic burden of advanced liver disease among patients with hepatitis C virus: a large state Medicaid perspective.

Menzin J, White LA, Nichols C, Deniz B.

BMC Health Serv Res. 2012 Dec 15;12:459. doi: 10.1186/1472-6963-12-459.

PMID:
23241078
[PubMed - indexed for MEDLINE]
6.

Cost of chronic hepatitis B infection in the United States.

Lee TA, Veenstra DL, Iloeje UH, Sullivan SD.

J Clin Gastroenterol. 2004 Nov-Dec;38(10 Suppl 3):S144-7.

PMID:
15602162
[PubMed - indexed for MEDLINE]
7.

The cost-effectiveness of testing for hepatitis C in former injecting drug users.

Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, Stein K.

Health Technol Assess. 2006 Sep;10(32):iii-iv, ix-xii, 1-93.

PMID:
16948891
[PubMed - indexed for MEDLINE]
8.

Advances in the treatment of hepatitis C.

Lawrence SP.

Adv Intern Med. 2000;45:65-105. Review.

PMID:
10635046
[PubMed - indexed for MEDLINE]
9.

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome.

Alter HJ, Seeff LB.

Semin Liver Dis. 2000;20(1):17-35. Review.

PMID:
10895429
[PubMed - indexed for MEDLINE]
10.

The costs of not treating hepatitis C virus infection in injecting drug users in New Zealand.

Sheerin IG, Green FT, Sellman JD.

Drug Alcohol Rev. 2003 Jun;22(2):159-67.

PMID:
12850902
[PubMed - indexed for MEDLINE]
11.

Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.

Saab S, Hunt DR, Stone MA, McClune A, Tong MJ.

Liver Transpl. 2010 Jun;16(6):748-59. doi: 10.1002/lt.22072.

PMID:
20517909
[PubMed - indexed for MEDLINE]
12.

Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.

Bird SM, Goldberg DJ, Hutchinson SJ.

J Epidemiol Biostat. 2001;6(3):243-65; discussion 279-85.

PMID:
11437088
[PubMed - indexed for MEDLINE]
13.

Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.

Hornberger J, Torriani FJ, Dieterich DT, Bräu N, Sulkowski MS, Torres MR, Green J, Patel K.

J Clin Virol. 2006 Aug;36(4):283-91. Epub 2006 Jun 9.

PMID:
16765638
[PubMed - indexed for MEDLINE]
14.

Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection.

Tencer T, Friedman HS, Li-McLeod J, Johnson K.

J Manag Care Pharm. 2007 Nov-Dec;13(9):790-8.

PMID:
18062730
[PubMed - indexed for MEDLINE]
15.

Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis.

Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB.

Am J Gastroenterol. 2003 Mar;98(3):679-90.

PMID:
12650806
[PubMed - indexed for MEDLINE]
16.

Outcome of hospital care of liver disease associated with hepatitis C in the United States.

Kim WR, Gross JB Jr, Poterucha JJ, Locke GR 3rd, Dickson ER.

Hepatology. 2001 Jan;33(1):201-6.

PMID:
11124837
[PubMed - indexed for MEDLINE]
17.

Cost of chronic hepatitis B infection in South Korea.

Yang BM, Kim CH, Kim JY.

J Clin Gastroenterol. 2004 Nov-Dec;38(10 Suppl 3):S153-7.

PMID:
15602164
[PubMed - indexed for MEDLINE]
18.

Simulation of hepatitis C based on a mandatory reporting system.

Sagmeister M, Renner EL, Mullhaupt B, Wong JB.

Eur J Gastroenterol Hepatol. 2002 Jan;14(1):25-34.

PMID:
11782572
[PubMed - indexed for MEDLINE]
19.

Economic evaluation for hepatitis C.

Grieve R, Roberts J.

Acta Gastroenterol Belg. 2002 Apr-Jun;65(2):104-9.

PMID:
12148430
[PubMed - indexed for MEDLINE]
20.

Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.

Yuan Y, Iloeje UH, Hay J, Saab S.

J Manag Care Pharm. 2008 Jan-Feb;14(1):21-33.

PMID:
18240879
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk